MHRA Report Highlights the Vital Role of Test Drug Labelling
The latest report from the MHRA contains a sober reminder of the importance of adequate labelling of experimental drugs.
Last week, the MHRA published its GCP Inspections Reports covering the 161 inspections it carried out in the year to 31stMarch 2011.
Poor handling of data featured in several cases – especially confidential participant data being revealed. However, the most tragic error involved poor packaging and labelling of IMP (Investigational Medicinal Product) and the provisi...
To continue reading this story get free access